Cardiac effects of current treatments of chronic obstructive pulmonary disease

The Lancet Respiratory Medicine

Volumn 4, Issue 2, 2016, Pages 149-164

  Lahousse, Lies ^a,b   Verhamme, Katia M ^b   Stricker, Bruno H ^b,c   Brusselle, Guy G ^a,b  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c Healthcare Inspectorate   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACLIDINIUM BROMIDE; ANTIBIOTIC AGENT; BECLOMETASONE; BETA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; DIURETIC AGENT; FLUTICASONE; FLUTICASONE FUROATE PLUS VILANTEROL; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; GLUCOSE; GLYCOPYRRONIUM BROMIDE; GLYCOPYRRONIUM BROMIDE PLUS INDACATEROL; INDACATEROL; LONG ACTING BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; LONG ACTING MUSCARINIC RECEPTOR BLOCKING AGENT; MUSCARINIC M3 RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; OLODATEROL; PHOSPHODIESTERASE IV INHIBITOR; PLACEBO; POTASSIUM; SALMETEROL; THEOPHYLLINE DERIVATIVE; TIOTROPIUM BROMIDE; UMECLIDINIUM; UNCLASSIFIED DRUG; UNINDEXED DRUG; VILANTEROL; MACROLIDE; PHOSPHODIESTERASE INHIBITOR; THEOPHYLLINE;

ANGINA PECTORIS; ATRIAL FIBRILLATION; ATRIOVENTRICULAR BLOCK; CARDIOVASCULAR DISEASE; CATARACT; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CONGESTIVE HEART FAILURE; CONSTIPATION; CORONARY ARTERY OBSTRUCTION; CUSHING DISEASE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG APPROVAL; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY POWDER INHALER; ECG ABNORMALITY; GLUCOSE BLOOD LEVEL; HEADACHE; HEART ARRHYTHMIA; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART PALPITATION; HEART VENTRICLE EXTRASYSTOLE; HUMAN; HYPERTENSION; HYPOKALEMIA; MAINTENANCE THERAPY; MONOTHERAPY; MULTICENTER STUDY (TOPIC); NAUSEA; OROPHARYNGEAL IRRITATION; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; POLYPHARMACY; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROGNOSIS; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SOFT MIST INHALER; SUPRAVENTRICULAR PREMATURE BEAT; SUPRAVENTRICULAR TACHYCARDIA; TACHYCARDIA; TREMOR; URINE RETENTION; XEROSTOMIA; CHEMICALLY INDUCED; HEART DISEASE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; HEART DISEASES; HUMANS; MACROLIDES; MUSCARINIC ANTAGONISTS; PHOSPHODIESTERASE INHIBITORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; THEOPHYLLINE;

EID: 84958109521     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(15)00518-4     Document Type: Review

References (87)

1. Cavaillès A, Brinchault-Rabin G, Dixmier A, et al. Comorbidities of COPD. Eur Respir Rev 2013, 22:454-475.
2. Chacko A, Carpenter DO, Callaway L, Sly PD Early-life risk factors for chronic nonrespiratory diseases. Eur Respir J 2015, 45:244-259.
3. Mannino DM, Thorn D, Swensen A, Holguin F Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J 2008, 32:962-969.
4. Lahousse L, Tiemeier H, Ikram MA, Brusselle GG Chronic obstructive pulmonary disease and cerebrovascular disease: A comprehensive review. Respir Med 2015, 109:1371-1380.
5. Divo M, Cote C, de Torres JP, et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012, 186:155-161. the BODE Collaborative Group.
6. Sin DD, Anthonisen NR, Soriano JB, Agusti AG Mortality in COPD: Role of comorbidities. Eur Respir J 2006, 28:1245-1257.
7. Feary JR, Rodrigues LC, Smith CJ, Hubbard RB, Gibson JE Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care. Thorax 2010, 65:956-962.
8. Zvezdin B, Milutinov S, Kojicic M, et al. A postmortem analysis of major causes of early death in patients hospitalized with COPD exacerbation. Chest 2009, 136:376-380.
9. Sidney S, Sorel M, Quesenberry CP, DeLuise C, Lanes S, Eisner MD COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program. Chest 2005, 128:2068-2075.
10. Lahousse L, Niemeijer MN, van den Berg ME, et al. Chronic obstructive pulmonary disease and sudden cardiac death: the Rotterdam study. Eur Heart J 2015, 36:1754-1761.
11. Vestbo J, Hurd SS, Agustí AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013, 187:347-365.
12. Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet 2012, 380:37-43.
13. Brusasco V Reducing cholinergic constriction: the major reversible mechanism in COPD. Eur Respir Rev 2006, 195:32-36.
14. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008, 359:1543-1554. the UPLIFT Study Investigators.
15. Celli B, Decramer M, Kesten S, Liu D, Mehra S, Tashkin DP Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009, 180:948-955. the UPLIFT Study Investigators.
16. Singh S, Loke YK, Furberg CD Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008, 300:1439-1450.
17. Michele TM, Pinheiro S, Iyasu S The safety of tiotropium-the FDA's conclusions. N Engl J Med 2010, 363:1097-1099.
18. Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 1994, 272:1497-1505.
19. Anthonisen NR, Connett JE, Enright PL, Manfreda J Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med 2002, 166:333-339. the Lung Health Study Research Group.
20. Halpin DMG, Dahl R, Hallmann C, Mueller A, Tashkin D Tiotropium handihaler and respimat in COPD: a pooled safety analysis. Int J Chron Obstruct Pulmon Dis 2015, 10:239-259.
21. Dong Y-H, Lin H-H, Shau W-Y, Wu Y-C, Chang C-H, Lai M-Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomised controlled trials. Thorax 2013, 68:48-56.
22. Verhamme KMC, Afonso A, Romio S, Stricker BC, Brusselle GGO, Sturkenboom MCJM Use of tiotropium Respimat Soft Mist Inhaler versus HandiHaler and mortality in patients with COPD. Eur Respir J 2013, 42:606-615.
23. Wise RA, Anzueto A, Cotton D, et al. Tiotropium Respimat inhaler and the risk of death in COPD. N Engl J Med 2013, 369:1491-1501. the TIOSPIR Investigators.
24. D'Urzo AD, Kerwin EM, Chapman KR, et al. Safety of inhaled glycopyrronium in patients with COPD: a comprehensive analysis of clinical studies and post-marketing data. Int J Chron Obstruct Pulmon Dis 2015, 10:1599-1612.
25. Trivedi R, Richard N, Mehta R, Church A Umeclidinium in patients with COPD: a randomised, placebo-controlled study. Eur Respir J 2014, 43:72-81.
26. Suissa S, Patenaude V, Lapi F, Ernst P Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax 2013, 68:1029-1036.
27. Brusselle GG, Bracke K, Lahousse L Targeted therapy with inhaled corticosteroids in COPD according to blood eosinophil counts. Lancet Respir Med 2015, 3:416-417.
28. Decramer ML, Hanania NA, Lötvall JO, Yawn BP The safety of long-acting β2-agonists in the treatment of stable chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2013, 8:53-64.
29. 2-agonists, alone or in combination with inhaled corticosteroids, in chronic obstructive pulmonary disease (COPD): a risk-benefit analysis. Pharmacol Ther 2011, 130:114-143.
30. Wilchesky M, Ernst P, Brophy JM, Platt RW, Suissa S Bronchodilator use and the risk of arrhythmia in COPD: part 1: Saskatchewan cohort study. Chest 2012, 142:298-304.
31. Wilchesky M, Ernst P, Brophy JM, Platt RW, Suissa S Bronchodilator use and the risk of arrhythmia in COPD: part 2: reassessment in the larger Quebec cohort. Chest 2012, 142:305-311.
32. Gershon A, Croxford R, Calzavara A, et al. Cardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary disease. JAMA Intern Med 2013, 173:1175-1185.
33. Newnham DM Asthma medications and their potential adverse effects in the elderly: recommendations for prescribing. Drug Saf 2001, 24:1065-1080.
34. Hawkins NM, Virani S, Ceconi C Heart failure and chronic obstructive pulmonary disease: the challenges facing physicians and health services. Eur Heart J 2013, 34:2795-2803.
35. Bristow MR, Ginsburg R, Umans V, et al. Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure. Circ Res 1986, 59:297-309.
36. Au DH, Lemaitre RN, Curtis JR, Smith NL, Psaty BM The risk of myocardial infarction associated with inhaled beta-adrenoceptor agonists. Am J Respir Crit Care Med 2000, 161:827-830.
37. Au DH, Udris EM, Fan VS, Curtis JR, McDonell MB, Fihn SD Risk of mortality and heart failure exacerbations associated with inhaled beta-adrenoceptor agonists among patients with known left ventricular systolic dysfunction. Chest 2003, 123:1964-1969.
38. Au DH, Udris EM, Curtis JR, McDonell MB, Fihn SD Association between chronic heart failure and inhaled beta-2-adrenoceptor agonists. Am Heart J 2004, 148:915-920. the ACQUIP Investigators.
39. Macie C, Wooldrage K, Manfreda J, Anthonisen N Cardiovascular morbidity and the use of inhaled bronchodilators. Int J Chron Obstruct Pulmon Dis 2008, 3:163-169.
40. Cazzola M, Page CP, Rogliani P, Matera MG β2-agonist therapy in lung disease. Am J Respir Crit Care Med 2013, 187:690-696.
41. Hanania NA, Sharafkhaneh A, Barber R, Dickey BF Beta-agonist intrinsic efficacy: measurement and clinical significance. Am J Respir Crit Care Med 2002, 165:1353-1358.
42. Gullotti D, Avila D, Lo Genco A, et al. Some cardiac effects during short-acting and long-acting (beta)2-agonist therapy in COPD subjects. Acta Med Mediterr 2006, 22:71-75.
43. Mann RD, Kubota K, Pearce G, Wilton L Salmeterol: a study by prescription-event monitoring in a UK cohort of 15,407 patients. J Clin Epidemiol 1996, 49:247-250.
44. Calverley PMA, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007, 356:775-789. the TORCH investigators.
45. Minami J, Hara T, Kobayashi A, Yoshida P Safety and effectiveness of salmeterol xinafoate/fluticasone propionate combination inhaler (Adoair 250 Diskus) in patients with chronic obstructive pulmonary disease: final report of long-term special drug use investigation. Ther Res 2014, 35:433-447.
46. Calverley PMA, Anderson JA, Celli B, et al. Cardiovascular events in patients with COPD: TORCH study results. Thorax 2010, 65:719-725. the TORCH Investigators.
47. Berger WE, Nadel JA Efficacy and safety of formoterol for the treatment of chronic obstructive pulmonary disease 2008, Elsevier, Philadelphia.
48. Cazzola M, Imperatore F, Salzillo A, et al. Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia. Chest 1998, 114:411-415.
49. Donohue JF, Hanania NA, Make B, et al. One-year safety and efficacy study of arformoterol tartrate in patients with moderate to severe COPD. Chest 2014, 146:1531-1542.
50. Rennard SI, Tashkin DP, McElhattan J, et al. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial. Drugs 2009, 69:549-565.
51. Tashkin DP, Rennard SI, Martin P, et al. Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial. Drugs 2008, 68:1975-2000.
52. Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003, 22:912-919.
53. Vestbo J, Anderson J, Brook RD, et al. The Study to Understand Mortality and Morbidity in COPD (SUMMIT) study protocol. Eur Respir J 2013, 41:1017-1022.
54. GSK and Theravance announce results from the SUMMIT COPD CV Survival Study GSK, (accessed Sept 8, 2015). http://www.gsk.com/en-gb/media/press-releases/2015/gsk-and-theravance-announce-results-from-the-summit-copd-cv-survival-study/.
55. Oba Y, Sarva ST, Dias S Efficacy and safety of long-acting β-agonist/long-acting muscarinic antagonist combinations in COPD: a network meta-analysis. Thorax 2015, published online Oct 21. 10.1136/thoraxjnl-2014-206732.
56. Wedzicha JA, Dahl R, Buhl R, et al. Pooled safety analysis of the fixed-dose combination of indacaterol and glycopyrronium (QVA149), its monocomponents, and tiotropium versus placebo in COPD patients. Respir Med 2014, 108:1498-1507.
57. Mahler DA, Kerwin E, Ayers T, et al. FLIGHT: efficacy and safety of QVA149 (indacaterol/glycopyrrolate) versus its monocomponents and placebo in patients with COPD. Am J Respir Crit Care Med 2015, 192:1068-1079.
58. Donohue JF, Niewoehner D, Brooks J, O'Dell D, Church A Safety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled study. Respir Res 2014, 15:78.
59. Celli B, Crater G, Kilbride S, et al. Once-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study. Chest 2014, 145:981-991.
60. Buhl R, Maltais F, Abrahams R, et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4). Eur Respir J 2015, 45:969-979.
61. Singh D, Ferguson GT, Bolitschek J, et al. Tiotropium + olodaterol shows clinically meaningful improvements in quality of life. Respir Med 2015, 109:1312-1319.
62. Singh D, Jones PW, Bateman ED, et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study. BMC Pulm Med 2014, 14:178.
63. D'Urzo AD, Rennard SI, Kerwin EM, Mergel V, Leselbaum AR, Caracta CF Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study. Respir Res 2014, 15:123. the AUGMENT COPD study investigators.
64. Lehrbuch der Arzneimittellehre un Arzneiverordnungslehre. Vierte neu bearbeitete auflage 1901, Tappeiner vDH, FCW Vogel Verlag, Leipzig.
65. Barr RG, Rowe BH, Camargo CA Methylxanthines for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2003, 2. CD002168.
66. Barnes PJ Theophylline. Am J Respir Crit Care Med 2013, 188:901-906.
67. Bleecker ER, Britt EJ Acute bronchodilating effects of ipratropium bromide and theophylline in chronic obstructive pulmonary disease. Am J Med 1991, 91:24S-27S.
68. ZuWallack RL, Mahler DA, Reilly D, et al. Salmeterol plus theophylline combination therapy in the treatment of COPD. Chest 2001, 119:1661-1670.
69. Bittar G, Friedman HS The arrhythmogenicity of theophylline. A multivariate analysis of clinical determinants. Chest 1991, 99:1415-1420.
70. Patel AK, Skatrud JB, Thomsen JH Cardiac arrhythmias due to oral aminophylline in patients with chronic obstructive pulmonary disease. Chest 1981, 80:661-665.
71. Sessler CN, Cohen MD Cardiac arrhythmias during theophylline toxicity. A prospective continuous electrocardiographic study. Chest 1990, 98:672-678.
72. Huerta C, Lanes SF, García Rodríguez LA Respiratory medications and the risk of cardiac arrhythmias. Epidemiology 2005, 16:360-366.
73. Lee TA, Pickard AS, Au DH, Bartle B, Weiss KB Risk for death associated with medications for recently diagnosed chronic obstructive pulmonary disease. Ann Intern Med 2008, 149:380-390.
74. Eiriksson CE, Writer SL, Vestal RE Theophylline-induced alterations in cardiac electrophysiology in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1987, 135:322-326.
75. Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009, 374:685-694. the M2-124 and M2-125 study groups.
76. Martinez FJ, Calverley PM, Goehring UM, Brose M, Fabbri LM, Rabe KF Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Lancet 2015, 385:857-866.
77. Van Bambeke F, Tulkens PM Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes. Drug Saf 2009, 32:359-378.
78. Aaron SD Management and prevention of exacerbations of COPD. BMJ 2014, 349:g5237.
79. Yamaya M, Azuma A, Takizawa H, Kadota J, Tamaoki J, Kudoh S Macrolide effects on the prevention of COPD exacerbations. Eur Respir J 2012, 40:485-494.
80. van Noord C, Eijgelsheim M, Stricker BH Drug- and non-drug-associated QT interval prolongation. Br J Clin Pharmacol 2010, 70:16-23.
81. Straus SM, Kors JA, De Bruin ML, et al. Prolonged QTc interval and risk of sudden cardiac death in a population of older adults. J Am Coll Cardiol 2006, 47:362-367.
82. Redfern WS, Carlsson L, Davis AS, et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 2003, 58:32-45.
83. Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM Azithromycin and the risk of cardiovascular death. N Engl J Med 2012, 366:1881-1890.
84. Svanström H, Pasternak B, Hviid A Use of azithromycin and death from cardiovascular causes. N Engl J Med 2013, 368:1704-1712.
85. Mosholder AD, Mathew J, Alexander JJ, Smith H, Nambiar S Cardiovascular risks with azithromycin and other antibacterial drugs. N Engl J Med 2013, 368:1665-1668.
86. Avorn J In defense of pharmacoepidemiology-embracing the yin and yang of drug research. N Engl J Med 2007, 357:2219-2221.
87. Roche N, Reddel HK, Agusti A, et al. Integrating real-life studies in the global therapeutic research framework. Lancet Respir Med 2013, 1:e29-e30. the Respiratory Effectiveness Group.